Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Information source: Hadassah Medical Organization
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Metastatic Solid Tumors
Intervention: Tumor Cell Vaccine (Biological)
Phase: Phase 1/Phase 2
Status: Recruiting
Sponsored by: Hadassah Medical Organization Official(s) and/or principal investigator(s):
Shimon Slavin, MD, Principal Investigator, Affiliation: Hadassah Medical Organization
Overall contact:
Shimon Slavin, MD, Phone: +972-2-6776561, Email: slavin@cc.huji.ac.il
Summary
The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in
patients with micro-metastatic disease and/or in patients at high risk disease progression.
The present study will use allogeneic tumor cell lines for tumor cell vaccines that share
MHC determinants with the patient aiming to overcome possible restriction of antigen
presentation.
Clinical Details
Official title: Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Study design: Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.
Secondary outcome: Investigate the feasibility of immune responses against cancer cells by combining allogeneic TCV with indomethacin, cimetidine, tetanus and rIL-2.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with measurable metastatic disease or disease resistant to chemotherapy or
with minimal residual disease at high risk to relapse.
Exclusion Criteria:
- Karnofsky less than 60%. Unrelated condition requiring the use of any cytotoxic
agents or immunosuppressive agents which may interfere with optimal immune response.
Locations and Contacts
Shimon Slavin, MD, Phone: +972-2-6776561, Email: slavin@cc.huji.ac.il
Hadassah Medical Organization, Jerusalem 911230, Israel; Recruiting
Arik Tzukert, DMD, Phone: +972-2-6776095, Email: arik@hadassah.org.il
Hadas Lemberg, PhD, Phone: +972-2-6777572, Email: lhadas@hadassah.org.il
Shimon Slavin, MD, Principal Investigator
Additional Information
Starting date: July 1998
Ending date: July 2005
Last updated: January 17, 2006
|
